AGHD

(redirected from Adult Growth Hormone Deficiency)
AcronymDefinition
AGHDAdult Growth Hormone Deficiency
References in periodicals archive ?
Mo et al., "Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database," The Journal of Clinical Endocrinology and Metabolism, vol.
Food and Drug Administration (FDA) granted marketing approval for MACRILEN, an oral growth hormone secretagogue (GHS) receptor agonist, to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD), which affects approximately 60,000 adults in the U.S.
to diagnose adult growth hormone deficiency, or AGHD.
Balercia, "Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk," Endocrine Journal, vol.
Now Humatrope is indicated for patients with severe adult growth hormone deficiency.
Initially commercialized by US Eli Lilly in 1987, Humatrope is currently approved for the treatment of adult growth hormone deficiency in more than 60 countries worldwide.
On December 20, 2017, the FDA granted Aeterna Zentaris marketing approval for Macrilen (macimorelin) to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD).
announced that the Marketing Authorization Application (MAA) for the use of Macrilen (macimorelin) for the evaluation of adult growth hormone deficiency (AGHD) has been accepted by the European Medicines Agency (EMA) for regulatory review.
(the "Company") today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.
Full browser ?